Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Cognition Therapeutics, Inc. CGTX
$1.56
-$0.03 (-1.89%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
47721836.00000000
-
week52high
6.27
-
week52low
1.07
-
Revenue
0
-
P/E TTM
-4
-
Beta
0.00000000
-
EPS
-0.88000000
-
Last Dividend
0.00000000
-
Next Earnings Date
23 мар 2023 г. в 12:00
Описание компании
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for the treatment of synucleinopathies, which include DLB and Parkinson's disease; and CT2074 to treat dry AMD. Cognition Therapeutics, Inc. was incorporated in 2007 and is headquartered in Purchase, New York.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Ladenburg Thalmann | Buy | 22 апр 2022 г. | |
| Oppenheimer | Outperform | 03 ноя 2021 г. | |
| Cantor Fitzgerald | Overweight | 29 сент 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| RICHSTONE ELLEN B | A | 10000 | 10000 | 29 ноя 2022 г. |
| Fletcher Aaron G.L. | A | 309748 | 1871 | 28 ноя 2022 г. |
| Fletcher Aaron G.L. | A | 2021906 | 12220 | 28 ноя 2022 г. |
| Fletcher Aaron G.L. | A | 326733 | 1973 | 28 ноя 2022 г. |
| Kreis Leslie W. | A | 309748 | 1871 | 28 ноя 2022 г. |
| Kreis Leslie W. | A | 2021906 | 12220 | 28 ноя 2022 г. |
| Kreis Leslie W. | A | 326733 | 1973 | 28 ноя 2022 г. |
| Kreis Leslie W. | A | 307877 | 8269 | 16 ноя 2022 г. |
| Kreis Leslie W. | A | 2009686 | 54009 | 16 ноя 2022 г. |
| Kreis Leslie W. | A | 324760 | 8722 | 16 ноя 2022 г. |
Новостная лента
Orin Hirschman Discloses Large Position in CGTX / Cognition Therapeutics
24/7 Wall Street
21 ноя 2022 г. в 11:47
Fintel reports that Hirschman Orin has filed a 13G form with the SEC disclosing ownership of 2,037,853 shares of Cognition Therapeutics Inc (CGTX).
CORRECTION -- Cognition Therapeutics to Report First Quarter 2022 Financial Results on May 11, 2022
GlobeNewsWire
04 мая 2022 г. в 17:54
PURCHASE, N.Y., May 04, 2022 (GLOBE NEWSWIRE) -- In a release issued under the same headline earlier today by Cognition Therapeutics, Inc. (NASDAQ: CGTX), please note that in the first paragraph of the release, the report date should be Wednesday, May 11, 2022, not Tuesday as previously stated. The corrected release follows:
Cognition Therapeutics to Present Preclinical Results Demonstrating Therapeutic Potential for Sigma-2 Receptor Modulators in Dry Age-Related Macular Degeneration
GlobeNewsWire
25 апр 2022 г. в 16:01
NEW YORK, April 25, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting a poster at the annual meeting of The Association for Research in Vision and Ophthalmology (ARVO) summarizing preclinical results showing that sigma-2 (σ-2) receptor modulators protect RPE cells and normalize key homeostatic processes disrupted in dry age-related macular degeneration (dry AMD). Cognition plans to initiate a Phase 2 clinical study for CT1812, the company's lead σ-2 receptor modulator, in patients with dry AMD.
Cognition Therapeutics, Inc. (CGTX) CEO Lisa Ricciardi on Q4 2021 Results - Earnings Call Transcript
Seeking Alpha
30 мар 2022 г. в 09:19
Cognition Therapeutics, Inc. (CGTX) CEO Lisa Ricciardi on Q4 2021 Results - Earnings Call Transcript
Cognition Therapeutics to Present Analyses from Clinical Studies of CT1812 in Patients with Alzheimer's Disease at AD/PD 2022
GlobeNewsWire
10 мар 2022 г. в 07:30
NEW YORK, March 10, 2022 (GLOBE NEWSWIRE) -- Cognition Therapeutics , Inc. (NASDAQ: CGTX), a clinical stage neuroscience company developing drugs that treat age-related degenerative diseases of the central nervous system and retina, will be presenting results from the clinical development program of CT1812, a small-molecule sigma-2 (σ-2) receptor modulator in development for Alzheimer's disease and other neurodegenerative disorders. Specifically, data will be presented from the Phase 1b SNAP study (COG0104; NCT03522129) and an interim analysis from the Phase 2 SHINE study (COG0201; NCT03507790) in two posters at the upcoming AD/PD™ 2022: the 16th International Conference on Alzheimer's & Parkinson's Diseases.